The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessAbstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,801–1,900 of 3,967
Behr, J., Nathan, S. D., Costabel, U., Albera, C., Wuyts, W. A., Glassberg, M. K., Haller, H., Alvaro, G., Gilberg, F., Samara, K. D., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02565-3 · Cited by 22
Self-citationDempsey, T. M., Thao, V., Helfinstine, D. A., Chang, Y.-H. H., Sangaralingham, L. R., & LIMPER, A. H. (2023) · European Respiratory Journal · doi:10.1183/13993003.01299-2023 · Cited by 16
Young, O. N., Bourke, J. E., & Widdop, R. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115839 · Cited by 17
Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions
Eriksson, O., & Velikyan, I. (2023) · Pharmaceuticals · doi:10.3390/ph16111540 · Cited by 14
Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6
Höhne, K., Wagenknecht, A., Maier, C., Engelhard, P., Goldmann, T., Schließmann, S. J., Plönes, T., Trepel, M., Eibel, H., Müller–Quernheim, J., et al. (2024) · Cells · doi:10.3390/cells13030238 · Cited by 13
“Currently, two new drugs have been approved for the therapy of mild to moderate fibrosis in IPF; however, although these drugs slow down disease progression, they do not induce a “restitutio ad integrum” [7,8].”
BackgroundKulkarni, T., Criner, G. J., Kass, D. J., Rosas, I. O., Scholand, M. B., Dilling, D. F., Summer, R. S., & Duncan, S. R. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02957-3 · Cited by 16
Zhang, H., Yang, Y., Cao, Y., & Guan, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02845-8 · Cited by 19
Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study
Özaltin, B., Chapman, R., Arfeen, M. Q. U., Fitzpatick, N., Hemingway, H., Direk, K., & Jacob, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02875-2 · Cited by 15
Wei, X., Jin, C., Li, D., Wang, Y., Zheng, S., Feng, Q., shi, N., Kong, W., Ma, X., & Wang, J. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.06.008 · Cited by 18
Understanding myofibroblast origin in the fibrotic lung
Zabihi, M., Felordi, M. S., Lingampally, A., Bellusci, S., Chu, X., & Agha, E. E. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.08.003 · Cited by 17
Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape
Cruwys, S., Hein, P., Humphries, B., & Black, D. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104207 · Cited by 20
ADAM Metallopeptidase domain 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1
Meng, Q., Bao, D., Liu, S., Huang, J., Guo, M., Dai, B., Ding, L., Xie, S., Meng, M., Lv, C., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01047-8 · Cited by 19
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future
Fiorentù, G., Bernardinello, N., Giulianelli, G., Cocconcelli, E., Balestro, E., & Spagnolo, P. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03129-3 · Cited by 15
Imaging of Idiopathic Pulmonary Fibrosis
Kusmirek, J. E., Martin, M. D., & Kanne, J. P. (2016) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2016.05.004 · Cited by 15
Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs
Holland, A. E. (2015) · Respirology · doi:10.1111/resp.12581 · Cited by 14
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
NAIR, G. B., Matela, A., Kurbanov, D., & Raghu, G. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1177461 · Cited by 14
Cotton, C. V., Spencer, L. G., New, R. P., & Cooper, R. G. (2016) · Rheumatology · doi:10.1093/rheumatology/kew320 · Cited by 14
The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia
Matsumura, T., Tsushima, K., Abe, M., Suzuki, K., Yamagishi, K., Matsumura, A., Ichimura, Y., Ikari, J., Terada, J., & Tatsumi, K. (2017) · The Clinical Respiratory Journal · doi:10.1111/crj.12704 · Cited by 15
Recent advances in managing idiopathic pulmonary fibrosis
Scelfo, C., Caminati, A., & Harari, S. A. (2017) · F1000Research · doi:10.12688/f1000research.10720.1 · Cited by 15
Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity
Serajeddini, H., Rogliani, P., & Mura, M. (2018) · Lung · doi:10.1007/s00408-018-0152-4 · Cited by 15
Tanaka, S., Miyoshi, K., Higo, H., Kurosaki, T., Otani, S., Sugimoto, S., Yamane, M., Kiura, K., Toyooka, S., & Oto, T. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.12.002 · Cited by 15
Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis
Ribes, B. M., Sancho-Chust, J. N., Talens, A., Arlandis, M., Herraiz-Robles, P., Chiner, E., & Aznar, T. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2018-001806 · Cited by 14
A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis
Moran‐Mendoza, O., Colman, R., Kalluri, M., Cabalteja, C., & Harle, I. A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1627204 · Cited by 15
Fibroblast Growth Factor Inhibitors in Lung Fibrosis: Friends or Foes?
Guzy, R. D. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0156ed · Cited by 14
Wang, Z., Qu, S., Zhu, J., Chen, F., & Ma, L. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-2842 · Cited by 16
Barranco‐Garduño, L. M., Buendía-Roldán, I., Rodriguez, J. J., González‐Ramírez, R., Cervantes-Nevarez, A., Neri-Salvador, J. C., Carrasco‐Portugal, M. D. C., Castañeda‐Hernández, G., Martínez‐Espinosa, K., Selman, M., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05279 · Cited by 17
Lung organoids and other preclinical models of pulmonary fibrosis
Oglesby, I. K., Schweikert, A., Fox, B., Redmond, C., Donnelly, S. C., & Hurley, K. (2021) · QJM · doi:10.1093/qjmed/hcaa281 · Cited by 15
Management of patients with fibrosing interstitial lung diseases
Morrow, L. E., Hilleman, D. E., & Malesker, M. A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab375 · Cited by 15
Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation
Koga, Y., Satoh, T., Kaira, K., Hachisu, Y., Ishii, Y., Yajima, T., Hisada, T., Yokoo, H., & Dobashi, K. (2021) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.1c00659 · Cited by 15
Joerns, E. K., Adams, T. N., Newton, C. A., Bermas, B. L., Karp, D., Batra, K., Torrealba, J., Davila, L., Reisch, J., Glazer, C., et al. (2021) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001808 · Cited by 13
Ding, L., Li, Y., Yang, Y., Song, S., Qi, H., Wang, J., Wang, Z., Zhao, J., Zhang, W., Zhao, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.762998 · Cited by 15
“PF is caused by occupational factors, autoimmune disorders, infections, and genetic factors, but the cause of this disease generally cannot be identified, which is called idiopathic PF (IPF) (Glass et al., 2020).”
BackgroundInfluential[Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
Kou, L., Kou, P., Luo, G., & Wei, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6197219 · Cited by 15
RetractedPost–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention
Yoon, H., & Uh, S. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2022.0053 · Cited by 14
Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population
Chérrez-Ojeda, I., Cortés-Telles, A., Gochicoa‐Rangel, L., Camacho-Leon, G., Mautong, H., Robles‐Velasco, K., & Faytong‐Haro, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091393 · Cited by 16
Zhang, H., Fang, S., Wang, C., Wang, W., Wu, J., Wang, C., Xu, B., & Zhang, Y. (2015) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0057 · Cited by 14
“Although transient clinical stability may be observed for a period of time, continued progression of IPF is inevitable and the prognosis of IPF is poor with a 5-year survival rate similar to those for cancers (King et al. , 2014).”
Reversal of lung fibrosis: an unexpected finding in survivor of acute respiratory distress syndrome
Chang, C.-H., Juan, Y. H., Hu, H., Kao, K. C., & Lee, C.-S. (2017) · QJM · doi:10.1093/qjmed/hcx190 · Cited by 12
Novel formononetin-7-sal ester ameliorates pulmonary fibrosis via MEF2c signaling pathway
Zhao, X., Qu, G., Song, C., Li, R., Liu, W., Lv, C., Song, X., Zhang, J., & Li, M. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.07.005 · Cited by 14
Impact of mediastinal lymph node enlargement on the prognosis of idiopathic pulmonary fibrosis
Sin, S., Lee, K. H., Hur, J. H., Lee, S. H., Lee, Y. J., Cho, Y., Yoon, H. I., Lee, J. H., Lee, C. T., & Park, J. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201154 · Cited by 13
Assayag, D., Camp, P. G., Fisher, J. H., Johannson, K. A., Kolb, M. R. J., Lohmann, T., Manganas, H., Morisset, J., Ryerson, C. J., Shapera, S., et al. (2018) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2018.1503456 · Cited by 16
Nakano, A., Ohkubo, H., Fukumitsu, K., Fukuda, S., Kanemitsu, Y., Takemura, M., Maeno, K., Ito, Y., Oguri, T., & Niimi, A. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1890-18 · Cited by 15
Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review
Lodhi, T., Hughes, G., Stanel, S. C., Chaudhuri, N., & Hayton, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01036-y · Cited by 16
Majewski, S., Szewczyk, K., Białas, A. J., Miłkowska-Dymanowska, J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101590 · Cited by 14
“Both nintedanib and pirfenidone, independently, have been shown to slow the disease progression limiting the decline of lung function in patients with IPF [45,46].”
BackgroundMoll, S. A., Wiertz, I. A., Vorselaars, A. D. M., Zanen, P., Ruven, H. J. T., van Moorsel, C. H. M., & Grutters, J. C. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0165 · Cited by 13
Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis
Wang, Y., Yella, J., Ghandikota, S. K., Cherukuri, T. C., Ediga, H. H., Madala, S. K., & Jegga, A. G. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620971143 · Cited by 16
“However, drug induced side-effect profiles of these two drugs are formidable and their therapeutic effects are suppressive rather than pulmonary fibrosis remission or reversal (3, 4).”
BackgroundMethodNémeth, J., Schundner, A., & Frick, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.611728 · Cited by 17
“To date, Nintedanib and Pirfenidone are the only approved drugs for treatment of IPF (47, 48).”
BackgroundChung, J. H., Montner, S. M., Thirkateh, P., Cannon, B., Barnett, S. D., & Nathan, S. D. (2021) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001230 · Cited by 14
Self-citationClarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis
Ley, B. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201706-423ed · Cited by 14
Li, D.-Y., Liu, X., Huang, J.-Y., Hang, W.-L., Yu, G.-R., & Xu, Y. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241232561 · Cited by 15
Luo, C., Huang, C., Zhu, Y., Zhou, Y., Qiao, Y., Shi, C., Gao, Y., Guo, Y., & Wei, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07573-5 · Cited by 21
Ma, M., Chu, Z., Quan, H., Li, H., Zhou, Y., Han, Y., Li, K., Pan, W., Wang, D., Yan, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1524654 · Cited by 22
Yu, W., Zhou, H., Goldin, J. G., Wong, W. K., & Kim, G. H. J. (2021) · Medical Physics · doi:10.1002/mp.14754 · Cited by 15
Chikhanie, Y. A., Veale, D., Vergès, S., & Hérengt, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106523 · Cited by 18
Minimal clinically important difference in idiopathic pulmonary fibrosis
Kang, M., Marts, L. T., Kempker, J. A., & Veeraraghavan, S. (2021) · Breathe · doi:10.1183/20734735.0345-2020 · Cited by 14
BMP1 is not required for lung fibrosis in mice
Ma, H., N’Diaye, E.-N., Caplazi, P., Huang, Z., Arlantico, A., Jeet, S., Wong, A., Brightbill, H. D., Li, Q., Wong, W. R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09557-3 · Cited by 13
Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know
Joerns, E. K., Adams, T. N., Sparks, J. A., Newton, C. A., Bermas, B. L., Karp, D. R., & Makris, U. E. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01072-8 · Cited by 14
2022 Brazilian Thoracic Association recommendations for long-term home oxygen therapy
Castellano, M. V. C. D. O., Pereira, L. F. F., Feitosa, P. H. R., Knorst, M. M., Salim, C., Rodrigues, M. M., Ferreira, E. V. M., Duarte, R., Togeiro, S. M., Stanzani, L. Z. L., et al. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20220179 · Cited by 23
Li, J., Yu, X., Xie, Y., Yang, S.-G., Zhao, L., Zhou, M., & Meng, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1053356 · Cited by 14
“Although more and more relevant treatment researches have been conducted or being conducted in IPF, only pifenidone and nintedanib obtained evidence-based efficacy and were recommended in the guidelines up to now (King et al., 2014; Richeldi et al., 2014; Raghu et al., 2015; Behr, 2016; Cottin et al., 2017; Behr et al…”
BackgroundUpperton, S., Beirne, P., Bhartia, B., Boland, A. C., Bradley, C., Crosbie, P. A. J., Darby, M., Eckert, C., Gabe, R., Hancock, N., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001490 · Cited by 13
Shakeel, I., Afzal, M., Islam, A., Sohal, S. S., & Hassan, M. I. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100167 · Cited by 16
Idiopathic Pulmonary Fibrosis: From Common Microscopy to Single-Cell Biology and Precision Medicine
Selman, M., & Pardo, A. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202309-1573pp · Cited by 14
Lucà, S., Pagliuca, F., Perrotta, F., Ronchi, A., Mariniello, D. F., Natale, G., Bianco, A., Fiorelli, A., Accardo, M., & Franco, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073618 · Cited by 19
Advances in common in vitro cellular models of pulmonary fibrosis
Li, D., Zhang, X., Song, Z., Zhao, S., Huang, Y., Qian, W., & Cai, X. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12756 · Cited by 14
Yu, D., Yin, G., Lei, J., Gong, Y., Zheng, L., He, D., Lei, L., & Sun, L. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1382244 · Cited by 18
Cepharanthine attenuates pulmonary fibrosis via modulating macrophage M2 polarization
Bao, J., Liu, C. X., Song, H., Mao, Z., Qu, W., Yu, F., Shen, Y., Jiang, J., Chen, X., Wang, R., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03250-z · Cited by 14
Boateng, E., Bonilla-Martinez, R., Ahlemeyer, B., Garikapati, V., Alam, M. R., Trompak, O., Oruqaj, G., El-Merhie, N., Seimetz, M., Ruppert, C., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02935-7 · Cited by 14
O’Donnell, D. E., Neder, J. A., Harle, I. A., & Moran‐Mendoza, O. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1251843 · Cited by 14
Chuang, H.-M., Ho, L.-I., Huang, M., Huang, K.-L., Chiou, T., Lin, S., Su, H.-L., & Harn, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103024 · Cited by 15
“Inhibition of TGF-β using approved clinical treatments for IPF (Pirfenidone) causes common side effects such as nausea and photosensitivity [8].”
MethodExisting and emerging treatments for idiopathic pulmonary fibrosis
Kolilekas, L., Papiris, S. A., & Bouros, D. E. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568244 · Cited by 15
Aschner, Y., Nelson, M., Brenner, M., Roybal, H. M., Beke, K. M., Meador, C., Foster, D. G., Correll, K. A., Reynolds, P. R., Anderson, K. C., et al. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00235.2019 · Cited by 15
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities
Cruwys, S., Hein, P., Humphries, B., & Black, D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.019 · Cited by 15
Kim, J. W., Barrett, K., Loke, Y. K., & Wilson, A. M. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100792 · Cited by 14
Functional parameters of small airways can guide bronchodilator use in idiopathic pulmonary fibrosis
Hu, P., Ko, H., Su, K., Feng, J., Su, W., Hsiao, Y., & Perng, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-75597-2 · Cited by 13
Fu, J., Lü, L., Wang, H., Hou, Y., & Dou, H. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51654 · Cited by 13
3-Carbamoyl-proxyl nitroxide radicals attenuate bleomycin-induced pulmonary fibrosis in mice
Assayag, M., Goldstein, S., Samuni, A., & Berkman, N. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.010 · Cited by 13
Cost drivers in the pharmacological treatment of interstitial lung disease
Maqhuzu, P. N., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2021) · Respiratory Research · doi:10.1186/s12931-021-01807-8 · Cited by 14
Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study
Radu, D. M., Freynet, O., Kambouchner, M., Boubaya, M., Nunès, H., Uzunhan, Y., Brillet, P., Guiraudet, P., Noorah, M. Z., Israël‐Biet, D., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.08.056 · Cited by 14
Zheng, J., Dong, H., Zhang, T., Ning, J., Xu, Y., & Cai, C. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.865052 · Cited by 17
“Currently, there are only two FDA-approved drugs for IPF (pirfenidone and nindanib), which do not prevent or reverse the progression of the disease or reduce mortality; they can only moderately reduce the rate of deterioration of lung function (King et al., 2014; Richeldi et al., 2014).”
BackgroundStandardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., Yokomura, K., Fukada, A., Inoue, Y., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02062-1 · Cited by 14
Physiotherapy management of interstitial lung disease
Holland, A. E. (2022) · Journal of physiotherapy · doi:10.1016/j.jphys.2022.06.006 · Cited by 15
Wu, X., Xiao, X., Chen, X., Yang, M., Hu, Z., Shuai, S., Fu, Q., Yang, H., & Du, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.948101 · Cited by 14
“This suggests that in future relevant experiments, researchers should try to use older rats or administer multiple doses to younger rats to optimize the animal model and demonstrate the characteristics of human IPF (Degryse et al., 2010).”
BackgroundInfluentialPiotrowski, W. J., Martusewicz-Boros, M. M., Białas, A. J., Barczyk, A., Batko, B. P., Błasińska, K., Boros, P. W., Górska, K., Grzanka, P., Jassem, E., et al. (2022) · Advances in respiratory medicine · doi:10.3390/arm90050052 · Cited by 15
Miao, Y., Li, X., Yang, Y., Zhang, J., Chen, L., Zhang, Q., Li, W., Liu, Y., Zhang, X., Gu, R., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109427 · Cited by 17
Liu, Y., Wu, J., Li, Z., Luo, Y., Zeng, F., & Shi, S. (2016) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-015-0316-z · Cited by 13
Avdeev, S. N. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-5-600-612 · Cited by 15
Huang, H. F., Feng, R. E., Li, S., Xu, K., Bi, Y. L., & Xu, Z. (2016) · Medicine · doi:10.1097/md.0000000000004113 · Cited by 13
Great expectations for simtuzumab in IPF fall short
Meyer, K. C. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30420-9 · Cited by 14
Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target
Fan, X., Xie, J., & Tian, J. (2017) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000204 · Cited by 13
Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis
Nambiar, A. M., Anzueto, A., & Peters, J. I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176312 · Cited by 13
Recent progress in systemic sclerosis-interstitial lung disease
Castelino, F. V., & Dellaripa, P. F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000544 · Cited by 13
Oishi, K., Hirano, T., Murata, Y., Hamada, K., Uehara, S., Suetake, R., Yamaji, Y., Asami‐Noyama, M., Edakuni, N., Ohata, S., et al. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619872890 · Cited by 16
Jones, I. C., Espíndola, M. S., Narayanan, R., Coelho, A. L., Habiel, D. M., Boehme, S. A., Ly, T. W., Bacon, K. B., & Hogaboam, C. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56393-z · Cited by 13
Emerging biomarkers in chronic lung allograft dysfunction
Shtraichman, O., & Diamond, J. M. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1738929 · Cited by 13
Drugs in phase I and phase II clinical trials for systemic sclerosis
Chung, M. P., & Chung, L. S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1743973 · Cited by 14
“Pirfenidone is generally well tolerated in patients with IPF, and compared with placebo, pirfenidone significantly reduced disease progression (as measured by the change in FVC % predicted), increased progression-free survival [67,68], and reduced the risk of mortality [67,69].”
BackgroundLi, D., Liu, Y., & Wang, B. (2020) · PubMed · Cited by 15
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Brereton, C. J., & Jo, H. E. (2020) · Breathe · doi:10.1183/20734735.0086-2020 · Cited by 13
Urushiyama, H., Jo, T., Hasegawa, W., Ando, T., Sakamoto, Y., Uda, K., Matsui, H., Fushimi, K., Yasunaga, H., & Nagase, T. (2021) · Respirology · doi:10.1111/resp.14044 · Cited by 15
Speca, S., Dubuquoy, C., Rousseaux, C., Chavatte, P., Desreumaux, P., & Spagnolo, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257281 · Cited by 13
Joannes, A., Morzadec, C., Duclos, M., Llamas‐Gutierrez, F., Chiforeanu, D. C., Naourès, C. L., Latour, B. R. D., Rouzé, S., Wollin, L., Jouneau, S., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115972 · Cited by 13
Long-term management of patients with end-stage lung diseases
Briganti, D. F., & D’Ovidio, F. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.007 · Cited by 19
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.